Elevated Rates Of Obesity And Heart Disease Fuel Expansion Of The Type 2 Diabetes Market: A Key Driver Powering Type 2 Diabetes Market Growth In 2025

The Type 2 Diabetes Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Type 2 Diabetes Market Size and Its Estimated Growth Rate?
Over the recent years, the size of the type 2 diabetes market has seen substantial growth. It is projected to expand from $48.14 billion in 2024 to $51.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.9%. The surge witnessed in previous periods can be attributed to factors such as changes in lifestyle and diet, an aging population, advancements in pharmaceuticals, and public health initiatives.

The market size for type 2 diabetes is predicted to experience robust expansion in the coming years, reaching a value of $72.22 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include the worldwide diabetes epidemic, personalized medicine, developments in technology, as well as changes in healthcare policies. Key trends for the forecast period are anticipated to be digital health and telemedicine, proactive prevention and early intervention, utilization of artificial intelligence (AI) and machine learning (ML), and metabolic surgery.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13050

How Are Emerging Segments Shaping the Type 2 Diabetes Market Landscape?
The type 2 diabetes market covered in this report is segmented -

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Other Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes
2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications
3) By End-User: Children, Adults

Subsegments:
1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Sulfonylureas And Other Insulin Secretagogues: Glimepiride, Glipizide, Glyburide
6) By Biguanides: Metformin
7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Which Growth Factors Are Influencing Type 2 Diabetes Market Expansion?
The increasing prevalence of obesity and heart disease is projected to fuel the expansion of the type 2 diabetes market. Obesity, defined as a health condition where there's an unhealthy accumulation of body fat, and heart disease, which encompasses a variety of conditions affecting the heart and blood vessels, are significant contributors to this market's growth. Excessive body weight escalates the risk of insulin resistance, leading to elevated blood sugar levels and consequently, the onset of type 2 diabetes. Concurrently, high blood sugar levels can impair blood vessels and nerves responsible for controlling the heart and blood vessels, thus causing heart disease. For example, in March 2024, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, noted that roughly one in eight people globally grappled with obesity. This figure includes 2.5 billion adults (18 years and older), with 890 million of them being obese. In this demographic, 43% were deemed overweight and 16% were categorized as obese. Furthermore, the population of overweight children under five hit the 37 million mark. Therefore, the escalating rates of obesity and heart disease are triggering the surge in the type 2 diabetes market. In the perpetuation of the type 2 diabetes market, the growing geriatric population is expected to play a pivotal role. This population is categorized as individuals who are 65 years or older. Elderly individuals are more susceptible to various diseases due to their advanced age and decreased immunity. Ageing amplifies the odds of encountering Type 2 diabetes-related complications such as hypoglycemia (low blood sugar), kidney failure, and heart diseases. These complications can lead to both sudden and gradual microvascular and cardiovascular issues. For instance, as of July 2023, the World Health Organization stated that one in six people around the world would be over 60 by 2030. By 2050, individuals aged 60 and above would double to 2.1 billion. Between 2020 and 2050, the world will see a surge of 426 million individuals aged 80 or older. Therefore, the ballooning geriatric population is pushing the growth of the type 2 diabetes market.

Who Are the Dominant Players Across Different Type 2 Diabetes Market Segments?
Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health.

What Are the Latest Developing Trends in the Type 2 Diabetes Market?
Leading firms in the type 2 diabetes market are pushing boundaries with innovative products like Mounjaro, aimed at improving safety standards and effectiveness for people suffering from diabetes. The goal is to raise the bar in terms of efficacy, safety, and ease of diabetes management in comparison to existing treatments. The thrust of innovation in diabetes medication development is on refining blood sugar control, reducing adverse effects, and tackling other related health issues. For example, in May 2022, U.S. pharmaceutical giant Eli Lilly and Co., gained approval from the U.S. Food and Drug Administration, a US government agency, for Mounjaro (tripeptide) injection, intended as an adjunct to diet and exercise to better control blood sugar levels in adults diagnosed with type 2 diabetes. Tirzepatide presents a pioneering, dual-targeted solution for type 2 diabetes and is administered via weekly injections. It targets two blood sugar-regulating hormones, like glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 facilitates an increase in insulin production and a decrease in glucagon production, whereas GIP boosts insulin production. Tirzepatide offers a bright new ray of hope for people with type 2 diabetes, including those who haven't found success with other treatment modalities.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Geographic Regions Are Expected to Dominate the Type 2 Diabetes Market in the Coming Years?
North America was the largest region in the type 2 diabetes market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Type 2 Diabetes Market?
2. What is the CAGR expected in the Type 2 Diabetes Market?
3. What Are the Key Innovations Transforming the Type 2 Diabetes Industry?
4. Which Region Is Leading the Type 2 Diabetes Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.